

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA208; Trastuzumab for the treatment of HER2-positive metastatic gastric cancer

This guidance was issued November 2010 with a review date of August 2013.

Background

At the GE meeting of 13 August 2013 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	The guidance should be transferred to the 'static guidance list'.
Rationale for selecting this proposal	Since the publication of TA208, no significant new clinical evidence has been identified that is likely to lead to a change in the current guidance. Although the cost effectiveness would be affected by taking account of the average prices that the NHS pays for generic medicines, the impact of this is not expected to be significant enough to change the recommendation in TA 208. It is therefore appropriate that the guidance should be transferred to the 'static guidance list'.

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	The guidance should be transferred to the 'static guidance list'.
--	---

Respondent	Response to proposal	Details	Comment from Technology Appraisals
Medicines and Healthcare Products Regulatory Agency	No objection	We are content with NICE proposal to move the guidance to static list.	Comment noted.
Royal College of Nursing	No comments	There are no comments to submit on behalf of the Royal College of Nursing to inform on the review proposal of the above appraisal.	No action.
Royal College of Physicians National Cancer Research Institute Royal College of Radiologists Association of Cancer Physicians	Agree	<p>The NCRI/RCP/RCP/ACP/JCCO have reviewed the NICE proposal with regard to the above guidance. Overall, our experts are content for the guidance to be moved to the static list as they are not aware of any new emergent evidence to warrant re-appraisal at this time.</p> <p>However, our experts wish to stress that when trastuzumab comes off patent (and is therefore cheaper) it might be worth considering whether the use of trastuzumab in the IHC 2+/FISH +ve cohort would become cost-effective. The current NICE guidance only includes IHC 3+.</p>	<p>Comment noted.</p> <p>Guidance that has been moved to the static list can be considered for review if evidence that could potentially change the decision emerges.</p>

No response received from:

<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none">• Roche Products <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none">• Afiya Trust• Black Health Agency• Cancer52• Cancer Black Care• Cancer Equality• Equalities National Council• GIST Support UK• Helen Rollason Cancer Charity• Independent Age• Independent Cancer Patients Voice• Macmillan Cancer Support• Maggie's Centres• Marie Curie Cancer Care• Muslim Council of Britain• Muslim Health Network• Oesophogael Patients Association• Rarer Cancers Foundation• Sarcoma UK• South Asian Health Foundation• Specialised Healthcare Alliance• Tenovus <p><u>Professional groups</u></p> <ul style="list-style-type: none">• Association of Anaesthetists• Association of Surgeons of Great Britain and Ireland	<p><u>General</u></p> <ul style="list-style-type: none">• Allied Health Professionals Federation• Board of Community Health Councils in Wales• British National Formulary• Care Quality Commission• Commissioning Support Appraisals Service• Department of Health, Social Services and Public Safety for Northern Ireland• Healthcare Improvement Scotland• National Association of Primary Care• National Pharmacy Association• NHS Alliance• NHS Commercial Medicines Unit• NHS Confederation• Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none">• Abbott Gmbh & Co. (capecitabine)• Accord Healthcare (5-fluorouracil, capecitabine, cisplatin, epirubicin, oxaliplatin)• Actavis UK (capecitabine, epirubicin, oxaliplatin)• AstraZeneca (capecitabine)• Bristol-Myers Squibb (cisplatin)• Cardinal Health Martindale Products (epirubicin)• Fresenius Kabi (epirubicin)• Hameln Pharmaceuticals (epirubicin)• Hospira UK (5-fluorouracil, cisplatin, epirubicin, oxaliplatin)• Krka (capecitabine)• Medac UK (5-fluorouracil, epirubicin, oxaliplatin)
--	---

- Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
- British Association for Services to the Elderly
- British Geriatrics Society
- British Institute of Radiology
- British Psychosocial Oncology Society (BPOS)
- British Society of Gastroenterology
- Cancer Network Pharmacists Forum
- Cancer Research UK
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Pathologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- United Kingdom Clinical Pharmacy Association
- United Kingdom Oncology Nursing Society

Others

- Department of Health
- NHS England
- NHS Knowsley CCG
- NHS Newcastle West CCG
- Welsh Government

- Mylan UK (epirubicin, oxaliplatin)
- Pfizer (cisplatin, epirubicin)
- Roche Products (capecitabine)
- Sandoz (cisplatin)
- Sanofi (oxaliplatin)
- Strides Arcolab (epirubicin)
- Sun pharmaceuticals (oxaliplatin)
- Teva UK (capecitabine, cisplatin, epirubicin, oxaliplatin)
- Wockhardt UK (5-fluorouracil, cisplatin, epirubicin, oxaliplatin)
- Zentiva UK (oxaliplatin)

Relevant research groups

- Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
- CORE- Digestive Disorders Foundation
- Health Research Authority
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Network
- National Institute for Health Research
- Research Institute for the Care of Older People

Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

- National Clinical Guidelines Centre
- National Collaborating Centre for Cancer

	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none">• Public Health England• Public Health Wales NHS Trust
--	---

GE paper sign-off: Helen Knight, Associate Director – Technology Appraisals Programme

Contributors to this paper:

Technical Lead: Nwamaka Umeweni

Project Manager: Andrew Kenyon

2 October 2013